收费全文 | 5129129篇 |
免费 | 415754篇 |
国内免费 | 16049篇 |
耳鼻咽喉 | 71864篇 |
儿科学 | 164944篇 |
妇产科学 | 134574篇 |
基础医学 | 768897篇 |
口腔科学 | 144104篇 |
临床医学 | 473593篇 |
内科学 | 946703篇 |
皮肤病学 | 124172篇 |
神经病学 | 433219篇 |
特种医学 | 198307篇 |
外国民族医学 | 1064篇 |
外科学 | 767107篇 |
综合类 | 139824篇 |
现状与发展 | 24篇 |
一般理论 | 2867篇 |
预防医学 | 430990篇 |
眼科学 | 119624篇 |
药学 | 366116篇 |
26篇 | |
中国医学 | 14278篇 |
肿瘤学 | 258635篇 |
2021年 | 60556篇 |
2019年 | 67645篇 |
2018年 | 84504篇 |
2017年 | 65686篇 |
2016年 | 72408篇 |
2015年 | 84944篇 |
2014年 | 119978篇 |
2013年 | 187646篇 |
2012年 | 154451篇 |
2011年 | 163173篇 |
2010年 | 140075篇 |
2009年 | 137343篇 |
2008年 | 145551篇 |
2007年 | 155961篇 |
2006年 | 162409篇 |
2005年 | 156291篇 |
2004年 | 156157篇 |
2003年 | 145448篇 |
2002年 | 133672篇 |
2001年 | 200282篇 |
2000年 | 197252篇 |
1999年 | 176851篇 |
1998年 | 76411篇 |
1997年 | 70999篇 |
1996年 | 69119篇 |
1995年 | 64674篇 |
1994年 | 58460篇 |
1993年 | 54265篇 |
1992年 | 130047篇 |
1991年 | 124777篇 |
1990年 | 120185篇 |
1989年 | 116592篇 |
1988年 | 107447篇 |
1987年 | 105429篇 |
1986年 | 99497篇 |
1985年 | 96807篇 |
1984年 | 78548篇 |
1983年 | 69075篇 |
1982年 | 51944篇 |
1981年 | 47963篇 |
1980年 | 44980篇 |
1979年 | 68413篇 |
1978年 | 53528篇 |
1977年 | 47070篇 |
1976年 | 43656篇 |
1975年 | 44577篇 |
1974年 | 49656篇 |
1973年 | 47602篇 |
1972年 | 44582篇 |
1971年 | 41234篇 |
Area covered: This review presents the management of irAEs resulting from checkpoint blockade, with a focus on rare irAEs.
Expert commentary: With the development of immuno-oncology and the expanding role of ICI, physicians have learnt to diagnose and treat most of the irAEs that can occur. This review provides an overview of current guidelines, previously published studies and our multidisciplinary team based practices. 相似文献
Areas covered: We discuss the current understanding of the HH pathway as it relates to normal hematopoiesis, the pathology of acute myeloid leukemia (AML), the rationale for and data from combination therapies including HH pathway inhibitors, and ultimately the prospects that might offer promise in targeting this pathway in AML.
Expert opinion: Efforts to target the HH pathway have been focused on impeding this disposition and restoring chemosensitivity to conventional myeloid neoplasm therapies. The year 2018 saw the first approval of a HH pathway inhibitor (glasdegib) for AML, though for an older population and in combination with an uncommonly-used therapy. Several other clinical trials with agents targeting modulators of HH signaling in AML and MDS are underway. Further study and understanding of the interplay between the numerous aspects of HH signaling and how it relates to the augmented survival of AML will provide a more reliable substrate for therapeutic strategies in patients with this poor-risk disease. 相似文献
Area covered: The current review is provided to update recent developments in the clinical application of cyclin/CDK inhibitors to breast cancer with a focus on the anti-tumor immune response.
Expert opinion: The cyclin D1 gene encodes the regulatory subunit of a proline-directed serine-threonine kinase that phosphorylates several substrates. CDKs possess phosphorylation site selectivity, with the phosphate-acceptor residue preceding a proline. Several important proteins are substrates including all three retinoblastoma proteins, NRF1, GCN5, and FOXM1. Over 280 cyclin D3/CDK6 substrates have b\een identified. Given the diversity of substrates for cyclin/CDKs, and the altered thresholds for substrate phosphorylation that occurs during the cell cycle, it is exciting that small molecular inhibitors targeting cyclin D/CDK activity have encouraging results in specific tumors. 相似文献
Areas covered: This review summarizes the evolution of renal mass biopsy to its current state with respect to outcomes, indications, and clinical guidelines.
Expert opinion: With improved understanding of differential biological potential of renal cortical neoplasms combined with technical improvements in diagnostic yield and accuracy, utilization of renal mass biopsy is becoming an important adjunct to patient care in a broad range of clinical scenarios, including active surveillance, thermal ablation, and use of primary systemic therapy in localized and advanced settings. 相似文献